| Product Code: ETC9961784 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, the United States saw a significant decline in carcinoembryonic antigen import shipments, with a negative CAGR of -31.87% from 2020 to 2024. The top exporting countries to the USA were Austria, Metropolitan France, Italy, Germany, and Brazil. Despite the low concentration indicated by the Herfindahl-Hirschman Index (HHI), the growth rate plummeted by -39.06% from 2023 to 2024. This data suggests a challenging market environment for carcinoembryonic antigen imports into the United States in 2024.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Carcinoembryonic Antigen Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Carcinoembryonic Antigen Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Carcinoembryonic Antigen Market - Industry Life Cycle |
3.4 United States (US) Carcinoembryonic Antigen Market - Porter's Five Forces |
3.5 United States (US) Carcinoembryonic Antigen Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 United States (US) Carcinoembryonic Antigen Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in the US population |
4.2.2 Rising demand for early cancer detection and diagnosis |
4.2.3 Technological advancements in CEA testing methods |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for CEA testing |
4.3.2 High cost associated with CEA testing procedures |
4.3.3 Limited awareness about CEA testing among the general population |
5 United States (US) Carcinoembryonic Antigen Market Trends |
6 United States (US) Carcinoembryonic Antigen Market, By Types |
6.1 United States (US) Carcinoembryonic Antigen Market, By Application |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Carcinoembryonic Antigen Market Revenues & Volume, By Application, 2021- 2031F |
6.1.3 United States (US) Carcinoembryonic Antigen Market Revenues & Volume, By Colorectal Cancer, 2021- 2031F |
6.1.4 United States (US) Carcinoembryonic Antigen Market Revenues & Volume, By Pancreatic Cancer, 2021- 2031F |
6.1.5 United States (US) Carcinoembryonic Antigen Market Revenues & Volume, By Ovarian Cancer, 2021- 2031F |
6.1.6 United States (US) Carcinoembryonic Antigen Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.1.7 United States (US) Carcinoembryonic Antigen Market Revenues & Volume, By Thyroid Cancer, 2021- 2031F |
6.1.8 United States (US) Carcinoembryonic Antigen Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Carcinoembryonic Antigen Market Import-Export Trade Statistics |
7.1 United States (US) Carcinoembryonic Antigen Market Export to Major Countries |
7.2 United States (US) Carcinoembryonic Antigen Market Imports from Major Countries |
8 United States (US) Carcinoembryonic Antigen Market Key Performance Indicators |
8.1 Adoption rate of CEA testing among healthcare providers |
8.2 Number of research studies and clinical trials focusing on CEA testing |
8.3 Patient engagement and participation in CEA screening programs |
9 United States (US) Carcinoembryonic Antigen Market - Opportunity Assessment |
9.1 United States (US) Carcinoembryonic Antigen Market Opportunity Assessment, By Application, 2021 & 2031F |
10 United States (US) Carcinoembryonic Antigen Market - Competitive Landscape |
10.1 United States (US) Carcinoembryonic Antigen Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Carcinoembryonic Antigen Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |